反应详情

To a solution of [4-(2-{(1S,2R)-2-[1-(5-chloropyrimidin-2-yl)piperidin-4-yl]cyclopropyl}ethoxy)-2-fluorophenyl]acetic acid (80.0 mg, 0.184 mmol) and acetylenamine (11.68 mg, 0.190) in anhydrous DMF (1 mL) was added HOBt (28.2 mg, 0.184 mmol) followed by EDC (70.7 mg, 0.368 mmol) and the mixture was stirred at room temperature under nitrogen atmosphere for 16 hours. The mixture was diluted with water and ethyl acetate (5 mL). The layers were separated, the aqueous phase extracted with EtOAc (5 ml), the organic fractions combined, dried over sodium sulfate, filtered and concentrated in vacuo. The residue was purified via preparative TLC plate (1000 μM) using 40% ethyl acetate in hexane. The band containing product was removed from the plate and the silica washed with EtOAc. The filtrate was collected and the volatiles removed in vacuo to afford the title compound. HPLC/MS; 1.49 min (2 minute run), 471 (M+H)+.

1. customThe layers were separated
2. extractionthe aqueous phase extracted with EtOAc (5 ml)
3. dry with materialdried over sodium sulfate
4. filtrationfiltered
5. concentrationconcentrated in vacuo
6. customThe residue was purified via preparative TLC plate (1000 μM)
7. additionThe band containing product
8. customwas removed from the plate
9. washthe silica washed with EtOAc
10. customThe filtrate was collected
11. customthe volatiles removed in vacuo